BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.
  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

819 results

Results per page: 10 20 30

Dear Doctor Letter (Rote-Hand-Brief) on Samsca® (tolvaptan): Risk of too rapid rise of serum sodium PDF, 585KB, File is accessible Date: 27. March 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: tolvaptan

The pharmaceutical manufacturer issues information on the risk of a too rapid rise of serum sodium levels due to the use of Samsca® (tolvaptan) and on how this risk can be reduced.

Information Letter on Mircera® PDF, 1MB, File is accessible Date: 26. March 2012 Topics: Pharmakovigilanz Type: Download

Active substance: methoxy-polyethylenglycol-epoetin beta

Information Letter on Vfend® PDF, 47KB, File is accessible Date: 12. March 2012 Topics: Pharmakovigilanz Type: Download

Active substance: voriconazole

Information Letter on Vfend® 200 mg powder for solution for infusion (voriconazole): Temporary shortage PDF, 47KB, File is accessible Date: 12. March 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: voriconazole

It is recommended to limit the use of the product to patients without alternative treatment options. An information letter with treatment recommendations has been circulated to treating physicians and pharmacies concerned.

Information Letter on Onglyza® PDF, 183KB, File is accessible Date: 08. March 2012 Topics: Pharmakovigilanz Type: Download

Active substance: saxagliptin

Additional information (available in German only):

Information Letter on Onglyza® (saxagliptin): Risk of serious hypersensitivity reactions and acute pancreatitis PDF, 183KB, File is accessible Date: 08. March 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: saxagliptin

The pharmaceutical manufacturer issues information on important new findings on the use of Onglyza® (saxagliptin) and the related risk of serious hypersensitivity reactions and acute pancreatitis.

Information Letter on Halaven® (eribulin): Danger of dosing errors PDF, 58KB, File is accessible Date: 05. March 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: eribulin

Danger of dosing errors due to the fact that the dose is stated differently in the EU compared to several other regions and in some publications.

Information Letter on Halaven® PDF, 58KB, File is accessible Date: 05. March 2012 Topics: Pharmakovigilanz Type: Download

Active substance: eribulin

Rote-Hand-Brief on Rasilez®, Rasilez HCT® and Rasilamlo® PDF, 87KB, File is accessible Date: 27. February 2012 Topics: Pharmakovigilanz Type: Download

Active substance: aliskiren

Dear Doctor Letter (Rote-Hand-Brief) on Rasilez®, Rasilez HCT® and Rasilamlo® (aliskiren): New contraindications and warnings in connection with the use of aliskiren-containing medicines PDF, 87KB, File is accessible Date: 27. February 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: aliskiren

Important information on new contraindications and warnings in connection with the use of aliskiren-containing medicinal products in combination with inhibitors of the angiotensin converting enzyme (ACE inhibitors) or angiotensin receptor …